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Available online 3 February 2016The Genea018 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying Htt gene CAG expansion of 46 repeats, indicative of Huntington Disease. Following ICM out-
growth on inactivatedhuman feeders, karyotypewas conﬁrmed as46, XXbyCGHand STR analysis demonstrated
a female Allele pattern. The hESC line had pluripotent cell morphology, 75% of cells expressed Nanog, 91% Oct4,
73% Tra1-60 and 96% SSEA4, gave a Pluritest pluripotency score of 31.12, Novelty of 1.45, demonstrated Alkaline
Phosphatase activity and tri-lineage teratoma formation. The cell line was negative for Mycoplasma and visible
contamination.
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Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was plated whole onto
irradiated human feeders (Detroit 551 HFF – 200,000 cells per organ
culture dish – 69,204 cells/cm2) in 20% KSR medium (Amit et al.,
2000) with 50 ng/mL FGF added fresh. Karyotyping and STR proﬁling
was performed at the ﬁrst cryobanking step from ICM outgrowths
maintained on feeders. Alkaline Phosphatase staining and teratoma
formation were performed from feeders. Cells were then enzymatically
passaged as single cells in M2 pluripotent cell maintenance medium
(Genea Biocells) and CGH/karyotyping/DNA proﬁling repeated as
well as immunoﬂuorescent pluripotent marker staining, Pluritest and
sterility testing performed.tp://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Morphology and karyotype of Genea018. A) Brightﬁeld (passage 52) growing on
human inactivated feeders. B) Alkaline Phosphatase activity (passage 9) on human
inactivated feeders. C) Karyotypic analysis (passage 6) showing 46, XX normal, female
karyotype.
Table 1
CGH analysis summary; Genea018 (passage 16, 4 enzymatic) reporting a female cell line
and no abnormalities detected.
CGH summary
Sample name Genea018 p16_TE4
Date reported 12th February 2013
Hybridisation balance Balanced hybridization was observed for all chromosomes,
relative to reference DNA
Copy number change No copy number changes above 400 kb were detected
Interpretation Female cell line — no abnormalities detected
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1. Karyotyping: Passage 6; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome counts was performed for 5
and 10 of the metaphases respectively.
2. DNA Proﬁling: Passage 8; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the cell
lines. https://www.thermoﬁsher.com/order/catalog/product/4322288
Pluripotency assessment
3. Immunoﬂuorescence: Passage 15 (12 on feeders, 3 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
4. Pluritest: Passage 16 (12 on feeders, 4 enzymatic); RNAwas collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012)
5. Alkaline Phosphatase: Passage 9; Genea018 grown on feeders were
stained as per manufacturers protocol using the Merck Millipore
Alkaline Phosphatase Detection Kit (SCR004)
6. Teratoma formation: Passage 43; Stem cells were received one day
prior to injection. On the day of injection cellswere harvested byman-
ual scraping, washed and resuspended in DMEM/20% KSR for injec-
tion. In both experiments, mice were anaesthetized before
intramuscular injection of cells into the left inner thigh muscle of the
hind leg. Approximately 1–2 × 106 cells (1×T25) in 50 μL were
injected permouse at one site only. Resultant teratomaswere excised,
ﬁxed, sectioned and stained for assessment of tissues from each of the
embryonic germ layers.
Sterility testing
7. Mycoplasma: Passage 13; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR
8. Microbial contamination: testing was performed in conjunction
with our QC measures. Cells were thawed and cultured in 7 mL
antibiotic free medium (Genea Biocells M2 medium) for 2–3 days
at 37 °C. A clear solution at ~48–72 h indicated lack of bacterial,
fungal or yeast contamination. Clarity of the solution was assessed
by Cell Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryos were fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed con-
sent form can be provided upon request). Donors have received nopayment or ﬁnancial beneﬁts for their donation. Genea018 has been
derived from a donated, fully commercially consented embryo, original-
ly created by assisted reproduction technology (ART) for the purpose of
procreation. The embryo was identiﬁed through pre-implantation
genetic diagnosis to be affected by a genetic mutation andwas declared
excess to reproductive needs. Derivation was performed under
Australian National Health and Medical Research Council (NHMRC)
licence 309710. This licence was issued to GENEA on 7 May 2007.
More information about the licence can be obtained from the NHMRC
Table 2
STR proﬁle; Genea018 (passage 8) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
SIVF-18p8 11, 14 29 10, 12 11, 12 16, 17 6, 9.3 13 11, 13 17, 25 13, 15.2 17, 18 8, 11 14, 17 12, 13 24, 25
425B. Dumevska et al. / Stem Cell Research 16 (2016) 423–426webpage at http://www.nhmrc.gov.au/health-ethics/human-embryos-
and-cloning/database-licences-authorising-use-excess-art-embryos
PGD analysis conclusion
Mutation; expansion of CAG (17 and 46 CAG repeats) in HTT gene.
Family tree; mother has 43 repeats; inherited from her mother. Hunting-
ton Disease (HD) affected. See Bradley et al. (2011) for sequencing
analysis.
Morphology
The derived stem cell line, Genea018, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A/B).
Genetic analysis
The cell line has been karyotyped by traditional methods (Fig. 1C,
Supplementary Fig. 1) and CGH (Table 1, Supplementary Fig. 2),
which demonstrated 46, XX karyotype consistent with original deriva-
tion and pre-implantation genetic diagnosis (PGD). Analysis of STRFig. 2. Pluripotency validation of Genea018. A) Immunoﬂuorescent staining (10×) of pluripo
15, 3 enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest pluripoten
black. D) Tri-lineage teratoma formation (passage 43) with (left) cartilage, bone, (middle) bonmarkers showed Allele pattern consistent with female genotype
(Table 2, Supplementary Fig. 3).
Pluripotency
Genea018 is pluripotent by;
1. Alkaline Phosphatase stain positivity (Fig. 1B)
2. Immunoﬂuorescence with 91% Nanog positive, 91% Oct4, 73%
Tra1-60 and 96% SSEA4 positive (Fig. 2A/quantiﬁed in B).
3. Pluritest with a pluripotency score of 31.12 and Novelty score of 1.45
(Fig. 2C).
4. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2D).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.006.tent cell markers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage
cy (left) and novelty (right) scores with Genea018 (passage 16, 4 enzymatic) outlined in
e, squamous epithelium and (right) gastrointestinal epithelium.
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